Zilentix develops groundbreaking therapy for brain tumors

Zilentix CEO Dr. Michael Schreiber sits at a desk with computer screens and scientific illustrations, smiling at the camera.
Zilentix CEO Dr. Michael Schreiber

ZilentixAltona into the tecHHub Hamburg in Innovationspark Altona Innovationspark Glioblastoma is the most common malignant form of brain tumor, and a definitive cure is not yet possible. The start-up company Zilentix has now developed a treatment method that promises a decisive breakthrough. This method uses transformed viruses as helpers. The deadly characteristics of glioblastoma Simply put...

Skip to content